Peter Salgo, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP; Michael Kolodziej, MD; Bryan Loy, MD; and Irwin W. Tischler, DO, highlight projects such as CEO Cancer Life Sciences Consortium’s Project Data Sphere, Yale and Janssen’s Yale School of Medicine’s Open Data Access Project, and the National Institutes of Health’s Big Data To Knowledge initiative, and discuss their roles in integrating data from key cancer trials.
Although the panelists agree that these programs and similar initiatives show great promise in terms of potentially influencing drug development and patient care in oncology, Dr Loy remarks that it remains to be seen whether the programs can collect data and process them into a form that is useful and relevant. Drs Fox and Klein add that financial and privacy barriers may prevent key stakeholders from accessing and using data.
According to Dr Kolodziej, patient demands, or consumerism, may drive the future development of oncology drugs. He explains that patients are now conducting their own research on the Internet before meeting with healthcare professionals. However, Dr Fox questions the level of influence that patients have with regard to drug development, and remarks that pharmaceutical companies determine where to invest their money in terms of research and development.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More